Shanghai Pharmaceuticals (02607.HK): B019 new indication receives clinical trial approval notice.

Wisdom Financial APP News, Shanghai Pharmaceuticals (02607.HK) released an announcement that its subsidiary Shanghai Pharmaceuticals Group Biotechnology Technology Co., Ltd. has independently developed the "B019" and received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration, allowing it to conduct clinical trials for refractory systemic lupus erythematosus.